Abstract

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1
Heinz Ludwig ... Niklas Zojer
Blood | VOL. 132
Heinz Ludwig, et. al.Heinz Ludwig ... Niklas Zojer
29 Nov 2018
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
...
Blood | VOL. 134
, et. al. ...
13 Nov 2019
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab
María-Victoria Mateos ... Paul G Richardson
Blood | VOL. 134
María-Victoria Mateos, et. al.María-Victoria Mateos ... Paul G Richardson
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Treatment of Relapsed/Refractory MCL
Elisabeth Silkenstedt ... Martin Dreyling
Blood | VOL. -
Elisabeth Silkenstedt, et. al.Elisabeth Silkenstedt ... Martin Dreyling
26 Jul 2024
JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results
Joseph A Pidala ... Brian C Betts
Blood | VOL. -
Joseph A Pidala, et. al.Joseph A Pidala ... Brian C Betts
24 Jul 2024
How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms with Tyrosine Kinase Gene Fusions
Andreas Reiter ... Nicholas C.P Cross
Blood | VOL. -
Andreas Reiter, et. al.Andreas Reiter ... Nicholas C.P Cross
24 Jul 2024
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and All RARG-Related Atypical APL
Xiaosu Zhou ... Hongxing Liu
Blood | VOL. -
Xiaosu Zhou, et. al.Xiaosu Zhou ... Hongxing Liu
24 Jul 2024
View more papers